Trial Profile
A European patient registry study of Melphalan in the treatment of multiple tumor types
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2016
Price :
$35
*
At a glance
- Drugs Melphalan (Primary)
- Indications Cancer; Uveal melanoma
- Focus Adverse reactions; Therapeutic Use
- 18 Oct 2016 According to a Delcath Systems media release, data from the study will be used as supportive evidence in our global Health Authority submissions.
- 30 Sep 2016 New trial record